Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025
LONDON and GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025, in Chicago. Autolus will have a poster presentation, which will include updated follow up from the CARLYSLE study in patients with severe refractory systemic lupus erythematosus (srSLE).
Abstract: 2458
Title: Obecabtagene autoleucel (obe-cel), a CD19-targeting autologous chimeric antigen receptor T-cell therapy (CAR T) with a fast off-rate binding domain, in patients with severe, refractory systemic lupus erythematosus (srSLE): preliminary results from the Phase I CARLYSLE study
Session date and time: Tuesday, October 28, 2025; 10:30am - 12:30pm Central Time
Presenting Author: Maria Leandro, MD
Summary: Initial findings from the ongoing CARLYSLE study of obe-cel in srSLE show a manageable safety profile, with no dose limiting toxicities (DLTs), immune effector cell-associated neurotoxicity syndrome (ICANS) or Grade ≥2 cytokine release syndrome (CRS). SLEDAI-2K score reduction and clinical benefit were observed in all patients. In addition, three patients who had a complete renal response. Updated data will be presented at the conference.
About Autolus Therapeutics plc
Autolus Therapeutics plc (NASDAQ:AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
[email protected]
